ChiCTR2300077933 版本V1.1 版本创建时间2024/07/06 20:27:21 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300077933 

最近更新日期:

Date of Last Refreshed on:

2023-11-24 09:05:33 

注册时间:

Date of Registration:

2023-11-24 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

一种新型无痛尿管在男性泌尿外科的应用:一项随机对照研究

Public title:

Application of a novel painless urinary tube in male urology: a randomized controlled study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

一种新型无痛尿管在男性泌尿外科的应用:一项随机对照研究

Scientific title:

Application of a novel painless urinary tube in male urology: a randomized controlled study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张红伟 

研究负责人:

张红伟 

Applicant:

Hongwei Zhang 

Study leader:

Hongwei Zhang 

申请注册联系人电话:

Applicant telephone:

+86 185 3023 3961

研究负责人电话:

Study leader's
telephone:

+86 185 3023 3961

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

465791339@qq.com

研究负责人电子邮件:

Study leader's E-mail:

465791339@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

河南省卫辉市健康路88号

研究负责人通讯地址:

河南省卫辉市健康路88号

Applicant address:

88 Health Road, Weihui City, Henan Province

Study leader's address:

88 Health Road, Weihui City, Henan Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

新乡医学院第一附属医院

Applicant's institution:

The First Affiliated Hospital of Xinxiang Medical College

研究负责人所在单位:

新乡医学院第一附属医院

Affiliation of the Leader:

The First Affiliated Hospital of Xinxiang Medical College

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

EC-023-460

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

新乡医学院第一附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital of Xinxiang Medical College

伦理委员会批准日期:

Date of approved by ethic committee:

2023-10-19 00:00:00

伦理委员会联系人:

赵嘉林

Contact Name of the ethic committee:

Jialin Zhao

伦理委员会联系地址:

河南省卫辉市健康路88号

Contact Address of the ethic committee:

88 Health Road, Weihui City, Henan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 176 5190 5765

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

新乡医学院第一附属医院

Primary sponsor:

The First Affiliated Hospital of Xinxiang Medical College

研究实施负责(组长)单位地址:

河南省卫辉市健康路88号

Primary sponsor's address:

88 Health Road, Weihui City, Henan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河南

市(区县):

Country:

China

Province:

Henan

City:

单位(医院):

新乡医学院第一附属医院

具体地址:

河南省卫辉市健康路88号

Institution
hospital:

The First Affiliated Hospital of Xinxiang Medical College

Address:

88 Health Road, Weihui City, Henan Province

经费或物资来源:

新乡医学院第一附属医院青年基金

Source(s) of funding:

Youth Fund of the First Affiliated Hospital of Xinxiang Medical College

研究疾病:

留置尿管  

Target disease:

indwelling catheter

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究的主要目的是评估无痛尿管在男性患者泌尿外科手术中的临床效果,包括术后疼痛缓解程度、膀胱刺激征、镇静情况、并发症发生率等指标。  

Objectives of Study:

The main objective of this study was to evaluate the clinical effect of painless urinary catheterization in male urological patients, including postoperative pain relief, bladder irritation, sedation, complication rate and other indicators.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

纳入男性患者,年龄大于18岁,美国麻醉医师协会(AmericanSocietyofanesthesologists)生理状态介于I-III之间,计划全麻下行择期泌尿外科手术的男性患者。

Inclusion criteria

In male patients, older than 18 years old, the American society of anesthesiologists (AmericanSocietyofanesthesologists) physiological state between the I - III, plan men haing electie urology surgery under general anesthesia patients.

排除标准:

文盲;精神状态改变;膀胱流出梗阻病史;膀胱过动(夜间大于3次或24小时大于8次);神经性膀胱炎;终末期肾病(每24h排尿量小于500ml);病态肥胖;中枢神经系统紊乱;长期滥用镇痛、精神等药物;凝血功能障碍;已知对利多卡因等其他麻醉药物过敏的;术后瞻望及认知功能障碍。

Exclusion criteria:

Illiterate; Altered mental state; History of bladder efflux obstruction; Bladder overactivity (more than 3 times at night or more than 8 times in 24 hours); Neurocystitis; End-stage renal disease (less than 500ml of urine every 24 hours); Morbid obesity; Central nervous system disorders; Long-term abuse of analgesic, psychotropic and other drugs; Coagulation dysfunction; Known allergy to other narcotic drugs such as lidocaine; Postoperative visual and cognitive dysfunction.

研究实施时间:

Study execute time:

From 2022-06-01 00:00:00 To 2023-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-01-01 00:00:00 To 2023-08-31 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

123

Group:

Observation group

Sample size:

干预措施:

一次性无痛硅胶导尿管

干预措施代码:

Intervention:

Disposable, painless silicone catheter

Intervention code:

组别:

对照组

样本量:

123

Group:

Control group

Sample size:

干预措施:

一次性硅胶导尿管

干预措施代码:

Intervention:

Disposable silicone catheter

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河南 

市(区县):

 

Country:

China

Province:

Henan

City:

单位(医院):

新乡医学院第一附属医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Xinxiang Medical College

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

疼痛

指标类型:

主要指标

Outcome:

Pain

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

导管相关膀胱刺激征

指标类型:

主要指标

Outcome:

Catheter associated bladder irritation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

镇静评分

指标类型:

次要指标

Outcome:

Sedation score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿路感染

指标类型:

次要指标

Outcome:

Urinary tract infection

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

留置尿管满意度

指标类型:

次要指标

Outcome:

Satisfaction with indwelling catheter

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

并发症

指标类型:

次要指标

Outcome:

Satisfaction with indwelling catheter

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 85 years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

采用随机数字表的方法产生随机序列,将符合纳入标准的患者随机分为两组,一组使用一次性无痛硅胶导尿管,另一组使用普通导尿管。

Randomization Procedure (please state who generates the random number sequence and by what method):

A random sequence was generated using a random number table method, and patients meeting the inclusion criteria were randomly divided into two groups, one group receiving a disposable painless silicone catheter and the other group receiving a conventional catheter.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲设计,确保研究人员和参与者不知晓分组情况

Blinding:

Double-blind design ensures that researchers and participants are unaware of the grouping

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究发表后6个月内,在临床试验公共管理平台(http://www.medresman.org.cn/pub/cn/proj/guide.aspx)共享。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within 6 months after the publication of the study, on the clinical trial public management platform( http://www.medresman.org.cn/pub/cn/proj/guide.aspx )Sharing.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-11-24 09:05:08